Literature DB >> 35015687

Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.

Kevin O McNerney1,2, Amanda M DiNofia1,3, David T Teachey1,3, Stephan A Grupp1,3, Shannon L Maude1,3.   

Abstract

SUMMARY: Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. See related article by Bailey et al., p. 136 (15). ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35015687      PMCID： PMC9245357          DOI： 10.1158/2643-3230.BCD-21-0203

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  17 in total

1.  Pharmacologic control of CAR-T cell function using dasatinib.

Authors:  Evan W Weber; Rachel C Lynn; Elena Sotillo; John Lattin; Peng Xu; Crystal L Mackall
Journal:  Blood Adv       Date:  2019-03-12

2.  First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection.

Authors:  Silvius Frimmel; Jan Schipper; Joerg Henschel; Tsui Tung Yu; Steffen R Mitzner; Sebastian Koball
Journal:  Liver Transpl       Date:  2014-12       Impact factor: 5.799

3.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

Review 4.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

5.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.

Authors:  Margherita Norelli; Barbara Camisa; Giulia Barbiera; Laura Falcone; Ayurzana Purevdorj; Marco Genua; Francesca Sanvito; Maurilio Ponzoni; Claudio Doglioni; Patrizia Cristofori; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Renato Ostuni; Chiara Bonini; Monica Casucci; Attilio Bondanza
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

6.  CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Authors:  Theodoros Giavridis; Sjoukje J C van der Stegen; Justin Eyquem; Mohamad Hamieh; Alessandra Piersigilli; Michel Sadelain
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

7.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

8.  Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.

Authors:  Daniel A Lichtenstein; Fiorella Schischlik; Lipei Shao; Seth M Steinberg; Bonnie Yates; Hao-Wei Wang; Yanyu Wang; Jon Inglefield; Alina Dulau-Florea; Francesco Ceppi; Leandro C Hermida; Kate Stringaris; Kim Dunham; Philip Homan; Parthav Jailwala; Justin Mirazee; Welles Robinson; Karen M Chisholm; Constance Yuan; Maryalice Stetler-Stevenson; Amanda K Ombrello; Jianjian Jin; Terry J Fry; Naomi Taylor; Steven L Highfill; Ping Jin; Rebecca A Gardner; Haneen Shalabi; Eytan Ruppin; David F Stroncek; Nirali N Shah
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

9.  IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells.

Authors:  E Dong; Xiao-Zhu Yue; Lin Shui; Bin-Rui Liu; Qi-Qi Li; Yun Yang; Hui Luo; Wei Wang; Han-Shuo Yang
Journal:  Signal Transduct Target Ther       Date:  2021-01-07

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

Authors:  Marcela V Maus; Sara Alexander; Michael R Bishop; Jennifer N Brudno; Colleen Callahan; Marco L Davila; Claudia Diamonte; Jorg Dietrich; Julie C Fitzgerald; Matthew J Frigault; Terry J Fry; Jennifer L Holter-Chakrabarty; Krishna V Komanduri; Daniel W Lee; Frederick L Locke; Shannon L Maude; Philip L McCarthy; Elena Mead; Sattva S Neelapu; Tomas G Neilan; Bianca D Santomasso; Elizabeth J Shpall; David T Teachey; Cameron J Turtle; Tom Whitehead; Stephan A Grupp
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751
View more
  3 in total

1.  Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.

Authors:  Caroline Diorio; Rawan Shraim; Regina Myers; Edward M Behrens; Scott Canna; Hamid Bassiri; Richard Aplenc; Chakkapong Burudpakdee; Fang Chen; Amanda M DiNofia; Saar Gill; Vanessa Gonzalez; Michele P Lambert; Allison Barz Leahy; Bruce L Levine; Robert B Lindell; Shannon L Maude; J Joseph Melenhorst; Haley Newman; Jessica Perazzelli; Alix E Seif; Simon F Lacey; Carl H June; David M Barrett; Stephan A Grupp; David T Teachey
Journal:  Clin Cancer Res       Date:  2022-09-01       Impact factor: 13.801

2.  Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Authors:  Stefanie R Bailey; Sonika Vatsa; Rebecca C Larson; Amanda A Bouffard; Irene Scarfò; Michael C Kann; Trisha R Berger; Mark B Leick; Marc Wehrli; Andrea Schmidts; Harrison Silva; Kevin A Lindell; Ashley Demato; Kathleen M E Gallagher; Matthew J Frigault; Marcela V Maus
Journal:  Blood Cancer Discov       Date:  2022-03-01

3.  Anakinra utilization in refractory pediatric CAR T-cell associated toxicities.

Authors:  Caroline Diorio; Anant Vatsayan; Aimee C Talleur; Colleen Annesley; Jennifer J Jaroscak; Haneen Shalabi; Amanda K Ombrello; Michelle Hudspeth; Shannon L Maude; Rebecca A Gardner; Nirali N Shah
Journal:  Blood Adv       Date:  2022-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.